Log In
Print
BCIQ
Print
Print this Print this
 

BMS-817378

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionSmall molecule that inhibits c-Met proto-oncogene (MET;HGFR) and VEGF receptor 2 (KDR/Flk-1; VEGFR-2)
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene) ; Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) kinase inhibitor; MET inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner

Simcere Pharmaceutical Group


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today